2[1]Cleland JG,Clark A.Has the survival of the heart failure population changed?Lessons from trials.Am J Cardiol,1999,83:112-119.
3[2]Matsumori A,Onok,Nishio R,et al.Amiodarone inhibits production of tumor necrosis factor-α by human mononuclear cells: a possible mechanism for its effect in heart failure.Circulation,1997,96(5):1 386-1 389.
4[3]Amiodarone Trials Meta-Analysis Investigators.Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure:meta-analysis of individual data from 6 500 patients in randomised trials.Lancet,1997,350:1 417-1 424.
5Antman EM, Anbe DT, Armstrong PW,et al.ACC/AHA guidlines for the management of patients with ST-elevation myocardial infarction-executive summary[J]. Circulation,2004,110:588
7Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology[J]. Arch Intern Med,2000,160:1 741
8The American Heart Association in Collaboration with the International Liais on Committee on Resuscitation. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 6: Advance cardiovascular life support. Section 5: Phamacology I: Agents for Arrhythmias[J]. Circulation, 2000, 102(Suppl 8): I 112
9Fuster V, Rydén LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation[J]. Eur Heart J,2001,22:1 852
